Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences
H.C. Wainwright23rd Annual Global Investment Conferencetaking place September 13-15, 2021. Catalyst’s pre-recorded presentation will be available for viewing on-demand beginning Monday, September 13, 2021, at 7:00 AM EDT for those registered for the event. Catalyst’s management will host virtual 1x1 meetings throughout the day.
Cantor Virtual Global Healthcare Conferencetaking place September 27– 30, 2021. Catalyst’s management will present on September 28that 1:20 PM EDT and will host virtual 1x1 meetings throughout the day. The webcast will be available on the Company’s website and a replay will be accessible for at least 14 days.
The presentation will be available on the Investor section of the company's website promptly following the scheduled presentation times.
Firdapse® is currently being evaluated in clinical trials for the treatment of MuSK-MG and has received Orphan Drug Designation from the FDA for myasthenia gravis.
For additional information about the company, please visit www.catalystpharma.com.
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for fiscal year 2020 and its other filings with the
Investor Relations Contact:
Mary Coleman Catalyst Pharmaceuticals(305) 420-3200 Mcoleman@catalystpharma.com Media Contact: David Schull Russo Partners(212) 845-4271 firstname.lastname@example.org
Source: Catalyst Pharmaceuticals, Inc.